Why Is Candel Therapeutics (CADL) Stock Down -8.30% Today?
Key Takeaways
- CADL shares fell roughly 8.3% intraday, trading near $10.39 versus a prior session close of $11.33.
- The decline extended a multi-session pullback that included a 6.9% drop the previous day, unwinding a large portion of the stock's late-summer rally.
- No single company-specific headline drove the move; selling reflected profit-taking, financing and dilution concerns, and fading momentum after a run to a 52-week high of $14.00.
- Widening second-quarter losses and a 45% year-over-year rise in shares outstanding have kept capital-raise worries front and center.
- Trading volume was elevated, and the stock slipped below key short-term technical levels.
- Investors are watching the planned fourth-quarter BLA filing for aglatimagene in prostate cancer and progress in the Phase 3 AURORA lung cancer trial.
Opening Summary
Candel Therapeutics, Inc. (CADL), a clinical-stage biopharmaceutical company based in Needham, Massachusetts, that develops off-the-shelf viral immunotherapies for solid tumors, extended its recent downturn on Thursday. The stock was down approximately 8.3% in intraday trading, changing hands near $10.39 compared with a prior close of $11.33 — a decline of about $0.94 per share. The move confirmed a decisively lower session for a name that has now surrendered much of the ground gained during its summer surge.
Profit-Taking After a Sharp Run-Up
The most immediate driver behind the selloff appears to be profit-taking rather than a single adverse announcement. CADL rallied from a 52-week low of $4.35 to an intraday peak of $14.00 in late August, a gain of more than 200% in under a year, fueled by positive Phase 3 data for its lead candidate aglatimagene besadenovec in localized prostate cancer and the company's plan to submit a Biologics License Application (BLA) in the fourth quarter of 2026. After such a steep advance, momentum-oriented traders have been quick to lock in gains, and the stock has drifted lower through early September.
Financing and Dilution Concerns
Underlying the technical selling is a persistent concern about how a cash-consuming, pre-revenue biotech will fund its late-stage pipeline. Second-quarter results showed a net loss of $38.91 million, a sharp widening from a loss of roughly $4.8 million a year earlier. Meanwhile, shares outstanding have increased by about 45% over the past year, a reminder that Candel has repeatedly tapped equity markets to support its programs. Recent securities filings tied to a shelf registration and prior capital raises have kept dilution risk in the conversation, giving investors an incentive to reduce exposure during periods of weakness.
Technical Breakdown and Market Context
The two-day slide has carried CADL below its 50-day moving average, a level that had acted as support during the rally, and left the shares trading well off their late-August peak. Volume ran above the stock's recent average, indicating conviction behind the selling rather than an isolated bout of low-liquidity volatility. The move has diverged from the broader market, suggesting stock-specific and biotech-sector dynamics — including elevated short interest of roughly 16% of the float, which can amplify downward swings — are at work rather than a broad risk-off wave.
What Comes Next for CADL
Looking ahead, the investment thesis remains tied to execution. The company expects to file its BLA for aglatimagene in prostate cancer during the fourth quarter of 2026, a milestone that could refocus attention on the stock's fundamentals. It is also advancing the global Phase 3 AURORA trial of aglatimagene in advanced non-small cell lung cancer and expects long-term survival data from its linoserpaturev program in recurrent glioblastoma. Traders will also be watching for the next quarterly earnings report and any capital-raising announcements. Risks include clinical or regulatory setbacks, further dilution, and continued volatility driven by the stock's high short interest.
Trending AI Robots
Tickeron's Trending AI Robots page highlights the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Only the top performers are curated into this section, giving traders a way to explore automated approaches to the market. Visit the page to see which bots are leading today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
CADL in upward trend: price may jump up because it broke its lower Bollinger Band on September 10, 2026
CADL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 39 of 41 cases where CADL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +10.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where CADL advanced for three days, in 213 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 97 of 114 cases where CADL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for CADL moved out of overbought territory on August 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 24 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CADL as a result. In 87 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for CADL turned negative on September 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 41 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CADL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. CADL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 81 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CADL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.873) is normal, around the industry mean (20.119). P/E Ratio (0.000) is within average values for comparable stocks, (27.503). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.525). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.180).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement